Critical Contrast: Atara Biotherapeutics (NASDAQ:ATRA) & Taysha Gene Therapies (NASDAQ:TSHA)
Critical Contrast: Atara Biotherapeutics (NASDAQ:ATRA) & Taysha Gene Therapies (NASDAQ:TSHA)
Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) and Taysha Gene Therapies (NASDAQ:TSHA – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.
Atara Biotherapeutics(納斯達克股票代碼:ATRA — 獲取評級)和 Taysha Gene Therapies(納斯達克股票代碼:TSHA — 獲取評級)都是小型醫療公司,但哪家是最佳投資?我們將根據兩家公司的股息、估值、分析師建議、風險、機構所有權、盈利能力和收益對比這兩家公司。
Insider and Institutional Ownership
內部所有權和機構所有權
34.3% of Taysha Gene Therapies shares are owned by institutional investors. 4.0% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 42.4% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Taysha Gene Therapeutics的股份中有34.3%歸機構投資者所有。4.0%的Atara Biotherapeuts股票由內部人士持有。相比之下,Taysha Gene Therapies的股份中有42.4%由內部人士持有。強大的機構所有權表明大型基金經理、對沖基金和捐贈機構認爲,從長遠來看,一家公司的表現將優於市場。
Analyst Recommendations
分析師建議
This is a breakdown of current recommendations and price targets for Atara Biotherapeutics and Taysha Gene Therapies, as provided by MarketBeat.
這是MarketBeat提供的Atara Biotherapeutics和Taysha Gene Therapes目前的建議和目標價格的明細。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Atara Biotherapeutics | 2 | 2 | 2 | 0 | 2.00 |
Taysha Gene Therapies | 0 | 1 | 10 | 0 | 2.91 |
賣出評級 | 保持收視率 | 買入評級 | 強勁的買入評級 | 評分分數 | |
阿塔拉生物療法 | 2 | 2 | 2 | 0 | 2.00 |
Taysha 基因療法 | 0 | 1 | 10 | 0 | 2.91 |
Risk & Volatility
風險與波動性
Atara Biotherapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Taysha Gene Therapies has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.
Atara Biotherapeutics的beta值爲1,這表明其股價的波動率與標準普爾500指數相似。相比之下,Taysha Gene Therapeutics的beta值爲1.45,這表明其股價的波動性比標準普爾500指數高45%。
Earnings & Valuation
收益與估值
This table compares Atara Biotherapeutics and Taysha Gene Therapies' revenue, earnings per share and valuation.
該表比較了Atara Biotherapeutics和Taysha Gene Therapies的收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Atara Biotherapeutics | $20.34 million | 22.20 | -$340.14 million | ($2.47) | -1.93 |
Taysha Gene Therapies | N/A | N/A | -$174.52 million | ($4.11) | -0.57 |
總收入 | 價格/銷售比率 | 淨收入 | 每股收益 | 市盈率 | |
阿塔拉生物療法 | 2,034 萬美元 | 22.20 | -3.4014 億美元 | (2.47 美元) | -1.93 |
Taysha 基因療法 | 不適用 | 不適用 | -1.7452 億美元 | (4.11 美元) | -0.57 |
Taysha Gene Therapies has lower revenue, but higher earnings than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.
Taysha Gene Therapies的收入較低,但收益高於Atara BiotherapeuticsAtara Biotherapeutics的交易市盈率低於Taysha Gene Therapeutics,這表明它目前是這兩隻股票中更實惠的一隻。
Profitability
盈利能力
This table compares Atara Biotherapeutics and Taysha Gene Therapies' net margins, return on equity and return on assets.
該表比較了Atara Biotherapeutics和Taysha Gene Therapies的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Atara Biotherapeutics | -348.49% | -125.38% | -71.22% |
Taysha Gene Therapies | N/A | -338.37% | -101.42% |
淨利潤 | 股本回報率 | 資產回報率 | |
阿塔拉生物療法 | -348.49% | -125.38% | -71.22% |
Taysha 基因療法 | 不適用 | -338.37% | -101.42% |
Summary
摘要
Taysha Gene Therapies beats Atara Biotherapeutics on 9 of the 13 factors compared between the two stocks.
Taysha Gene Therapies在兩隻股票比較的13個因素中有9個擊敗了Atara Biotherapeutics。
About Atara Biotherapeutics
關於阿塔拉生物療法
(Get Rating)
(獲取評分)
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
Atara Biotherapeutics, Inc. 是一家異體T細胞免疫療法公司,該公司率先爲實體瘤、血液系統癌和自身免疫性疾病等嚴重疾病的患者開發變革性療法。還爲醫療需求未得到滿足的患者提供現成的治療方法。其產品線包括 tab-cel、ATA188、ATA2271/ATA3271 和 ATA3219。該公司由 Isaac E. Ciechanover 於 2012 年 8 月 22 日創立,總部位於加利福尼亞州南舊金山。
About Taysha Gene Therapies
關於 Taysha 基因療法
(Get Rating)
(獲取評分)
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Taysha Gene Therapies, Inc. 是一家基因療法公司,專注於開發和商業化基於腺相關病毒的基因療法,用於治療中樞神經系統單基因疾病。它主要開發用於治療巨型軸突神經病的 TSHA-120;用於治療 Rett 綜合徵的 TSHA-102;用於治療 CLN1 疾病的 TSHA-121;用於治療 CLN1 疾病的 TSHA-118;用於治療 SLC13A5 缺陷的 TSHA-105;以及用於治療 GM2 神經節苷脂症的 TSHA-101。Taysha Gene Therapies, Inc. 與德克薩斯大學西南醫學中心建立了戰略合作伙伴關係,以開發和商業化變革性基因療法。該公司成立於2019年,總部位於德克薩斯州達拉斯。
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Atara Biotherapeutics 每日的新聞和評級 -在下面輸入您的電子郵件地址,通過Marketbeat.com的免費每日電子郵件時事通訊接收Atara Biotherapeutics及相關公司的最新新聞和分析師評級的簡明每日摘要。